Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Oxytetracycline

Classification: B

Drug products: Oxytetracyclin-Augensalbe Jenapharm, Oxytetral, Terracortril med polymyxin B, Terracortril med Polymyxin B, Terra-Cortril med polymyxin B, Terracortril®, Terracortril® med Polymyxin B, Terramycin®-polymyxin B, Terramycin-Polymyxin B

ATC code: D06AA03, D07CA01, J01AA06, S01AA04, S03CA04

Substances: oxytetracycline, oxytetracycline calcium, oxytetracycline dihydrate, oxytetracycline hydrochloride

Summary

Published controlled studies on differences between men and women regarding efficacy, safety and pharmacokinetics of oxytetracycline are lacking.

The present evidence concerning differences between men and women is limited and do not motivate differentiation in dosing or treatment.

Additional information

Pharmacokineticsand dosing

No studies with a clinical relevant sex analysis regarding the pharmacokinetics or dosing of oxytetracycline have been found.

Effects

No studies with a clinical relevant sex analysis regarding the effects of oxytetracycline have been found.

Adverse effects

No studies with a clinical relevant sex analysis regarding the adverse effects of oxytetracycline have been found.

Reproductive health issues

Regarding teratogenic aspects, please consult Janusmed Drugs and Birth Defects (in Swedish, Janusmed fosterpåverkan).

Updated: 2020-08-28

Date of litterature search: 2015-10-20

References

Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-04-05.] länk
Conicse. Stockholm: eHälsomyndigheten. 2015 [cited 2016-03-23.] länk

Authors: Maria Enghag, Desirée Loikas

Reviewed by: Mia von Euler

Approved by: Karin Schenck-Gustafsson